A malignant neoplasm originating from the surface ovarian epithelium. It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of canc...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding ovarian carcinoma is limited due to its complex nature and the variability in clinical presentation. As a condition that affects a significant number of women but lacks systematic genetic studies, comprehensive clinical characterization has been challenging. Additionally, the absence of identified genes and inheritance patterns contributes to the difficulty in understanding the disease's etiology fully.
To navigate ovarian carcinoma, consider consulting with an oncologist specializing in gynecologic cancers, as they will have the expertise necessary for tailored treatment options. Additionally, exploring clinical trials may provide access to cutting-edge therapies. Resources such as the National Cancer Institute (cancer.gov) can offer valuable information on treatment and support. Participating in clinical trials can also contribute to the understanding of ovarian carcinoma. Although no specific patient organizations are identified, connecting with broader cancer support groups may provide community and resources.
There are currently 1107 active clinical trials investigating various aspects of ovarian carcinoma, which reflects the ongoing efforts to improve treatment options. Notable orphan drugs in development include multiple novel compounds targeting different pathways. For more information on active trials, you can visit ClinicalTrials.gov and search for ovarian carcinoma: https://clinicaltrials.gov/search?cond=ovarian%20carcinoma.
Actionable guidance for navigating care for ovarian carcinoma
To navigate ovarian carcinoma, consider consulting with an oncologist specializing in gynecologic cancers, as they will have the expertise necessary for tailored treatment options. Additionally, exploring clinical trials may provide access to cutting-edge therapies. Resources such as the National Cancer Institute (cancer.gov) can offer valuable information on treatment and support. Participating in clinical trials can also contribute to the understanding of ovarian carcinoma. Although no specific patient organizations are identified, connecting with broader cancer support groups may provide community and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding ovarian carcinoma is limited due to its complex nature and the variability in clinical presentation. As a condition that affects a significant number of women but lacks systematic genetic studies, comprehensive clinical characterization has been challenging. Additionally, the absence of identified genes and inheritance patterns contributes to the difficulty in understanding the disease's etiology fully.
To navigate ovarian carcinoma, consider consulting with an oncologist specializing in gynecologic cancers, as they will have the expertise necessary for tailored treatment options. Additionally, exploring clinical trials may provide access to cutting-edge therapies. Resources such as the National Cancer Institute (cancer.gov) can offer valuable information on treatment and support. Participating in clinical trials can also contribute to the understanding of ovarian carcinoma. Although no specific patient organizations are identified, connecting with broader cancer support groups may provide community and resources.
There are currently 1107 active clinical trials investigating various aspects of ovarian carcinoma, which reflects the ongoing efforts to improve treatment options. Notable orphan drugs in development include multiple novel compounds targeting different pathways. For more information on active trials, you can visit ClinicalTrials.gov and search for ovarian carcinoma: https://clinicaltrials.gov/search?cond=ovarian%20carcinoma.
Actionable guidance for navigating care for ovarian carcinoma
To navigate ovarian carcinoma, consider consulting with an oncologist specializing in gynecologic cancers, as they will have the expertise necessary for tailored treatment options. Additionally, exploring clinical trials may provide access to cutting-edge therapies. Resources such as the National Cancer Institute (cancer.gov) can offer valuable information on treatment and support. Participating in clinical trials can also contribute to the understanding of ovarian carcinoma. Although no specific patient organizations are identified, connecting with broader cancer support groups may provide community and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding ovarian carcinoma is limited due to its complex nature and the variability in clinical presentation. As a condition that affects a significant number of women but lacks systematic genetic studies, comprehensive clinical characterization has been challenging. Additionally, the absence of identified genes and inheritance patterns contributes to the difficulty in understanding the disease's etiology fully.
To navigate ovarian carcinoma, consider consulting with an oncologist specializing in gynecologic cancers, as they will have the expertise necessary for tailored treatment options. Additionally, exploring clinical trials may provide access to cutting-edge therapies. Resources such as the National Cancer Institute (cancer.gov) can offer valuable information on treatment and support. Participating in clinical trials can also contribute to the understanding of ovarian carcinoma. Although no specific patient organizations are identified, connecting with broader cancer support groups may provide community and resources.
There are currently 1107 active clinical trials investigating various aspects of ovarian carcinoma, which reflects the ongoing efforts to improve treatment options. Notable orphan drugs in development include multiple novel compounds targeting different pathways. For more information on active trials, you can visit ClinicalTrials.gov and search for ovarian carcinoma: https://clinicaltrials.gov/search?cond=ovarian%20carcinoma.
Actionable guidance for navigating care for ovarian carcinoma
To navigate ovarian carcinoma, consider consulting with an oncologist specializing in gynecologic cancers, as they will have the expertise necessary for tailored treatment options. Additionally, exploring clinical trials may provide access to cutting-edge therapies. Resources such as the National Cancer Institute (cancer.gov) can offer valuable information on treatment and support. Participating in clinical trials can also contribute to the understanding of ovarian carcinoma. Although no specific patient organizations are identified, connecting with broader cancer support groups may provide community and resources.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 7 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.